Implantable intraocular quantitative medicine injection pump

Abstract

The invention discloses an implantable intraocular quantitative medicine injection pump which comprises a medicine guiding pipe and a medicine adding bag, wherein a medicine inlet and a medicine outlet are arranged on the medicine adding bag, and one end of the medicine guiding pipe is communicated with the medicine outlet. While in use, the medicine adding bag is filled with medicine liquid and is punctured at the cornea segment, the medicine guiding pipe is inserted, the medicine adding bag is extruded, and the medicine liquid flows into the vitreous body through the medicine guiding pipe. The capacity of the medicine adding bag can be designed into a quantity required for single medication, an operator does not require repeating measuring medicine quantity during each medication, and the working efficiency is increased. The device can quantitatively medicate the eye posterior segment for multiple times without intraocular operation, is safe for implantation and easy for taking out,can reduce intraocular infection risk, can realize long-term sustainable medication to form effective medicine concentration and can enhance the local curative effects of the medicine in the eyes. The purpose of treating a series of intractable eye diseases requiring overall or local frequent medication is achieved, and the invention has great economical and social benefits and is very applicableto clinic application.

Description

technical field [0001] The invention relates to an ophthalmic medical device, in particular to an implanted intraocular quantitative injection pump. Background technique [0002] Due to the complex physiological structure of the eye and the influence of the blood-ocular barrier, many drugs have little effect on the treatment of diseases of the posterior segment of the eye. [0003] At present, the traditional drug injection methods for posterior ocular diseases generally include systemic and local methods. The systemic method is intravenous injection. The waiting time for the contact process is long, the drug is easily swallowed by cells, the loss rate is high, and it is difficult to reach the effective drug concentration. It has toxic side effects on the body and increases the burden of medical expenses for patients. Topical means include eye drops, intravitreal injections, and intraocular implants of slow-release devices. Due to the effect of the corneal barrier, it is d...

AI Technical Summary

Problems solved by technology

Due to the effect of the corneal barrier, it is difficult for eye drops to reach the effective drug concentration in the posterior segment of the eye; intravitreal injection can make the drug directly reach the posterior segment of the eye, but the half-life of the drug in the vitreous is short, and repeated injections are required To achieve the purpose of treatment, it is easy to cause a series of complications such as infection, bleeding, retinal detachment, etc., which has the risk of inconvenient administration and serious side effects; there is also a slow-release device, which is placed in the vitreous and requires intraocular surgery, which may damage the eyeball. internal tissue damage

Images